Health insurance; required provisions regarding prior authorization for health care services.
SB1215 expands Virginia’s health insurance prior authorization rules, primarily by adding detailed contract requirements for carriers and participating providers. For prescription drugs, the bill requires carriers to accept prior authorization requests electronically, by fax, or by phone from approved systems, respond within short deadlines, explain denials, and maintain tracking and website-based transparency for formularies, forms, and procedures. It also limits when an approved drug authorization can be revoked, requires carriers to honor certain prior authorizations across carrier changes and plan changes, and creates special protections for some mental health medications and medication-assisted treatment for substance use disorder.
The bill also creates a separate new section governing prior authorization for other health care services. That section requires carriers to respond within 72 hours for expedited requests and seven calendar days for standard requests, disclose supplementation needed, and publish service lists, codes, procedures, forms, and annual prior authorization data. It further bars denial of claims when required prior authorization information was not properly posted, and allows emergency removal of prior authorization requirements during pandemics, natural disasters, or similar emergencies. The bill is set to take effect for the first enactment on January 1, 2027, and directs the Bureau of Insurance, with the Secretary of Health and Human Resources, to convene a work group and report on implementation readiness and related federal developments by November 1, 2025.
SB1215 amends Virginia insurance law by adding new mandatory contract terms for health carriers and participating providers, chiefly in Title 38.2. It imposes new procedural, transparency, and continuity-of-care requirements on prior authorization for prescription drugs and health care services, while carving out several exemptions, including Medicare, Medicaid, CHIP, federal employee and TRICARE coverage, certain supplemental and specialty policies, dental and optometric plans, and a narrow class of HMOs. The bill also limits the State Corporation Commission’s jurisdiction over individual disputes and authorizes the Commission to adopt implementing regulations. Providers and carriers will need to update electronic systems, website disclosures, and internal workflows to comply with the new timelines and reporting obligations.
The bill appears to have broad bipartisan support and little recorded opposition. It passed the Senate and House overwhelmingly, with committee reports showing unanimous or near-unanimous votes and floor passage in both chambers without any recorded nays. The overall sentiment reflected in the voting history suggests agreement that prior authorization processes should be made faster, more transparent, and less disruptive for patients and providers.
The main points of potential contention are operational and regulatory rather than ideological. Carriers may be concerned about the administrative burden of short response deadlines, mandatory electronic interoperability, website posting requirements, and limits on revoking approvals after a drug or service has already been scheduled or provided. Providers may favor the bill’s transparency and continuity protections but could face implementation costs for upgrading e-prescribing and electronic health record systems. The bill also includes several carve-outs and delayed effective dates, indicating that lawmakers were balancing access reforms against concerns about feasibility, federal alignment, and the readiness of insurers and health systems.